These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 33391859)
1. Use of oral rivaroxaban in cerebral venous thrombosis. Maqsood M; Imran Hasan Khan M; Yameen M; Aziz Ahmed K; Hussain N; Hussain S J Drug Assess; 2020 Dec; 10(1):1-6. PubMed ID: 33391859 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rivaroxaban in cerebral venous thrombosis: insights from a prospective cohort study. Pan L; Wang M; Zhou D; Ding Y; Ji X; Meng R J Thromb Thrombolysis; 2022 Apr; 53(3):594-600. PubMed ID: 34731403 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC; JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105 [TBL] [Abstract][Full Text] [Related]
4. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Field TS; Dizonno V; Almekhlafi MA; Bala F; Alhabli I; Wong H; Norena M; Villaluna MK; King-Azote P; Ratnaweera N; Mancini S; Van Gaal SC; Wilson LK; Graham BR; Sposato LA; Blacquiere D; Dewar BM; Boulos MI; Buck BH; Odier C; Perera KS; Pikula A; Tkach A; Medvedev G; Canfield C; Mortenson WB; Nadeau JO; Alshimemeri S; Benavente OR; Demchuk AM; Dowlatshahi D; Lanthier S; Lee AYY; Mandzia J; Suryanarayan D; Weitz JI; Hill MD; Stroke; 2023 Nov; 54(11):2724-2736. PubMed ID: 37675613 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Connor P; Sánchez van Kammen M; Lensing AWA; Chalmers E; Kállay K; Hege K; Simioni P; Biss T; Bajolle F; Bonnet D; Grunt S; Kumar R; Lvova O; Bhat R; Van Damme A; Palumbo J; Santamaria A; Saracco P; Payne J; Baird S; Godder K; Labarque V; Male C; Martinelli I; Morales Soto M; Motwani J; Shah S; Hooimeijer HL; Prins MH; Kubitza D; Smith WT; Berkowitz SD; Pap AF; Majumder M; Monagle P; Coutinho JM Blood Adv; 2020 Dec; 4(24):6250-6258. PubMed ID: 33351120 [TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for the treatment of cerebral venous thrombosis. Esmaeili S; Abolmaali M; Aarabi S; Motamed MR; Chaibakhsh S; Joghataei MT; Mojtahed M; Mirzaasgari Z BMC Neurol; 2021 Feb; 21(1):73. PubMed ID: 33588777 [TBL] [Abstract][Full Text] [Related]
7. Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis. Giles JA; Balasetti VKS; Zazulia AR Neurocrit Care; 2021 Dec; 35(3):783-788. PubMed ID: 34046861 [TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience. Bajko Z; Maier S; Motataianu A; Filep RC; Stoian A; Andone S; Balasa R Acta Neurol Belg; 2022 Feb; 122(1):105-111. PubMed ID: 33733345 [TBL] [Abstract][Full Text] [Related]
9. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. Shankar Iyer R; Tcr R; Akhtar S; Muthukalathi K; Kumar P; Muthukumar K Clin Neurol Neurosurg; 2018 Dec; 175():108-111. PubMed ID: 30396036 [TBL] [Abstract][Full Text] [Related]
10. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Yaghi S; Shu L; Bakradze E; Salehi Omran S; Giles JA; Amar JY; Henninger N; Elnazeir M; Liberman AL; Moncrieffe K; Lu J; Sharma R; Cheng Y; Zubair AS; Simpkins AN; Li GT; Kung JC; Perez D; Heldner M; Scutelnic A; Seiffge D; Siepen B; Rothstein A; Khazaal O; Do D; Kasab SA; Rahman LA; Mistry EA; Kerrigan D; Lafever H; Nguyen TN; Klein P; Aparicio H; Frontera J; Kuohn L; Agarwal S; Stretz C; Kala N; El Jamal S; Chang A; Cutting S; Xiao H; de Havenon A; Muddasani V; Wu T; Wilson D; Nouh A; Asad SD; Qureshi A; Moore J; Khatri P; Aziz Y; Casteigne B; Khan M; Cheng Y; Mac Grory B; Weiss M; Ryan D; Vedovati MC; Paciaroni M; Siegler JE; Kamen S; Yu S; Leon Guerrero CR; Atallah E; De Marchis GM; Brehm A; Dittrich T; Psychogios M; Alvarado-Dyer R; Kass-Hout T; Prabhakaran S; Honda T; Liebeskind DS; Furie K Stroke; 2022 Mar; 53(3):728-738. PubMed ID: 35143325 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of rivaroxaban in preventing cerebral venous thromboembolism: a systematic review and meta-analysis. Netha A; Mazhar S; Azhar A; Moeez A; Choradia A; Mohtashim A; Anees U; Ejaz U; Tariq MU; Jawad S Ann Med Surg (Lond); 2024 Apr; 86(4):2098-2104. PubMed ID: 38576935 [TBL] [Abstract][Full Text] [Related]
12. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. Ferro JM; Bendszus M; Jansen O; Coutinho JM; Dentali F; Kobayashi A; Aguiar de Sousa D; Neto LL; Miede C; Caria J; Huisman H; Diener HC; Int J Stroke; 2022 Feb; 17(2):189-197. PubMed ID: 33724104 [TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study. Khorvash F; Farajpour-Khanaposhtani MJ; Hemasian H; Saadatnia SM Curr J Neurol; 2021 Jul; 20(3):125-130. PubMed ID: 38011461 [No Abstract] [Full Text] [Related]
15. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066 [TBL] [Abstract][Full Text] [Related]
16. Treatment Failure of Cerebral Venous Thrombosis With Rivaroxaban: A Case Report and Narrative Review. Mohamed M; Musa M; Fadul A; Abdallah I; Najim M; Saeed A Cureus; 2022 Apr; 14(4):e23778. PubMed ID: 35382062 [TBL] [Abstract][Full Text] [Related]
17. Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis. Lurkin A; Derex L; Fambrini A; Bertoletti L; Epinat M; Mismetti P; Dargaud Y Cerebrovasc Dis; 2019; 48(1-2):32-37. PubMed ID: 31480062 [TBL] [Abstract][Full Text] [Related]
18. An Observational Study to Evaluate the Effectiveness of Rivaroxaban in the Management of Cerebral Venous Sinus Thrombosis. Fatima M; Asghar MS; Abbas S; Iltaf S; Ali A Cureus; 2021 Mar; 13(3):e13663. PubMed ID: 33824814 [TBL] [Abstract][Full Text] [Related]
19. Apixaban for the treatment of cerebral venous thrombosis: A case series. Rao SK; Ibrahim M; Hanni CM; Suchdev K; Parker D; Rajamani K; Mohamed W J Neurol Sci; 2017 Oct; 381():318-320. PubMed ID: 28991706 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Rollins BM; Silva MA; Donovan JL; Kanaan AO Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]